Abstract: Barrier films are prepared from a blend of two high density polyethylene blend components and a high performance organic nucleating agent. The two high density polyethylene blend components have substantially different melt indices. Large reductions in the moisture vapor transmission rate of the film are observed in the presence of the nucleating agent when the melt indices of the two blend components have a ratio of greater than 10/1. The resulting barrier films are suitable for the preparation of packaging for dry foods such as crackers and breakfast cereals.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: High density polyethylene (hdpe) containing from 500 to 20,000 ppm of talc is used to prepare barrier film which is resistant to water vapor transmission. The addition of talc reduces the formation of “dust” (i.e. abraded polyethylene particles) during the manufacture of packages from the barrier film. Preferred talc has a particle size of less than 10 microns.

Abstract: The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.

Abstract: The present application describes pyrazolobenzamides and derivatives thereof of Formula I: P4-P-M-M4??I or pharmaceutically acceptable salt forms thereof. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: A blend of ethylene homopolymers contains at least one blend component having a very low molecular weight and a narrow molecular weight distribution. The blend has surprisingly high density and low hexane extractables. The blend is suitable for the manufacture of a wide variety of plastic goods including extruded goods and molded goods. Plastic film prepared from the blends of this invention have a low Water Vapor Transmission Rate (“WVTR”).

Abstract: The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.

Abstract: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4 ??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract: Novel ethylene styrene interpolymers having atactic ES repeating units and an alternating structure substantially higher than that predicted using Bernoullian statistics may be prepared in the presence of a transition metal phosphinimine compound and an activator.

Abstract: An ethylene styrene copolymer having isolated styrene monomer units separated by 5 or 6 methylene groups as determined by 13C-NMR may be polymerized in the presence of an activator and a transition metal catalyst containing a phosphinimine ligand.

Abstract: Novel ethylene styrene interpolymers having atactic ES repeating units and an alternating structure substantially higher than that predicted using Bemoullian statistics may be prepared in the presence of a transition metal phosphinimine compound and an activator.

Abstract: An ethylene styrene copolymer having isolated styrene monomer units separated by 5 or 6 methylene groups as determined by 13C-NMR may be polymerized in the presence of an activator and a transition metal catalyst containing a phosphinimine ligand.

Abstract: Novel ethylene styrene interpolymers having atactic ES repeating units and an alternating structure substantially higher than that predicted using Bernoullian statistics may be prepared in the presence of a transition metal phosphinimine compound and an activator.

Abstract: Novel ethylene styrene interpolymers having triads with double reverse styrene incorporation (SSS) may be prepared in the presence of a transition metal phosphinimine compound and an activator.

Abstract: Novel ethylene styrene interpolymers having atactic ES repeating units and an alternating structure substantially higher than that predicted using Bernoullian statistics may be prepared in the presence of a transition metal phosphinimine compound and an activator.